Clinical Trial

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-09-26; most recent amendment 2026-01-23.
Status change: Recruiting → Active, Not Recruiting 2025-10-06
Status change: Not Yet Recruiting → Recruiting 2025-07-08
Trial Details
NCT Number NCT06620003
Lead Sponsor Albert B. Sabin Vaccine Institute
Collaborators: Biomedical Advanced Research and Development Authority
Conditions Marburg Virus Disease
Enrollment 200 participants
Start Date 2025-04-14
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-01-26